NCT02626312 2026-04-16
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
456 trialsNCT06453486 2026-04-16
ABLATE
University Health Network, Toronto
Phase 2 Recruiting
NCT01512589 2026-04-15
Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03161522 2026-04-15
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04481204 2026-04-15
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06960889 2026-04-14
A Retrospective Clinical Study Exploring Prognostic Factors in Esophageal Cancer Patients
Nanfang Hospital, Southern Medical University
Active not recruiting
NCT06958328 2026-04-08
LAP100
NRG Oncology
Phase 3 Recruiting
NCT03186898 2026-04-03
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
NRG Oncology
Phase 3 Active not recruiting
NCT06848465 2026-04-03
LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 1 Recruiting
NCT05108428 2026-04-01
Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT05515796 2026-04-01
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed
NCT04503694 2026-03-27
REGINA
Jules Bordet Institute
Phase 2 Active not recruiting
NCT04484909 2026-03-20
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1 Suspended
NCT02439008 2026-03-13
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
Centre Oscar Lambret
Phase NA Terminated
NCT07467590 2026-03-12
TRIUNITE-07
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Not yet recruiting
NCT03322267 2026-03-06
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
National Taiwan University Hospital
Phase 2 Completed
NCT07455019 2026-03-06
A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT04075305 2026-03-05
MOMENTUM
UMC Utrecht
Recruiting
NCT04522336 2026-03-05
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04857528 2026-03-04
Detecting HPV DNA in Anal and Cervical Cancers
University of Chicago
Recruiting
NCT07448142 2026-03-04
Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT07448493 2026-03-04
GASTROBRAIN
Blokhin's Russian Cancer Research Center
Active not recruiting
NCT07448662 2026-03-04
COLBRAIN
Blokhin's Russian Cancer Research Center
Active not recruiting
NCT07039162 2026-02-27
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
China Medical University Hospital
Phase 2 Recruiting
NCT06964568 2026-02-10
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
Fudan University
Phase 3 Recruiting
NCT07162506 2026-02-04
DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT04643366 2026-01-27
Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer
Virginia Commonwealth University
Phase 2 Recruiting
NCT07312422 2026-01-26
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
Zhejiang Provincial People's Hospital
Phase 1/2 Recruiting
NCT04821778 2026-01-21
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT03257163 2026-01-20
Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
Rutgers, The State University of New Jersey
Phase 2 Active not recruiting
NCT00508443 2026-01-15
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT00335816 2026-01-14
Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04229459 2026-01-14
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.
Rabin Medical Center
Phase 2 Active not recruiting
NCT04523818 2026-01-14
Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04539808 2026-01-14
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT03104439 2026-01-12
Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT07324018 2026-01-08
Spirulina Derivative for Radiation Esophagitis
West China Hospital
Phase 2 Not yet recruiting
NCT03921684 2026-01-05
Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients
Rabin Medical Center
Phase 2 Active not recruiting
NCT07291401 2025-12-18
Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC
Zhongnan Hospital
Phase 2 Not yet recruiting
NCT07179900 2025-12-11
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
NCT07274774 2025-12-10
SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT02481635 2025-12-08
A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer
University Health Network, Toronto
Phase 1/2 Active not recruiting
NCT02437071 2025-12-05
Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02639026 2025-11-25
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT03279237 2025-11-25
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
Massachusetts General Hospital
Phase 1 Completed
NCT02207465 2025-11-19
A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Active not recruiting
NCT05417386 2025-11-18
FOLFIRINOX + NIS793 in Pancreatic Cancer
Massachusetts General Hospital
Phase 1 Terminated
NCT06994299 2025-11-18
PRISM
Weill Medical College of Cornell University
Phase 2 Withdrawn
NCT06281886 2025-11-17
Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Active not recruiting
NCT07086469 2025-11-17
Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Recruiting